Reuters logo
BRIEF-Vanda receives negative opinion for marketing authorization from the EMA on Fanaptum
July 21, 2017 / 11:26 AM / 5 months ago

BRIEF-Vanda receives negative opinion for marketing authorization from the EMA on Fanaptum

July 21 (Reuters) - Vanda Pharmaceuticals Inc

* Vanda receives negative opinion for marketing authorization from the European Medicines Agency on Fanaptum™ for the treatment of schizophrenia

* Vanda Pharmaceuticals Inc - ‍Vanda intends to appeal this opinion and request a re-examination by CHMP​

* Vanda Pharmaceuticals Inc - ‍CHMP was of opinion that “benefits of Fanaptum did not outweigh its risks” and recommended against marketing authorization​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below